Tradename | Company | Number | Date | Products |
---|---|---|---|---|
GOCOVRI | Adamas Pharmaceuticals | N-208944 RX | 2017-08-24 | 2 products, RLD, RS |
OSMOLEX ER | Adamas Pharmaceuticals | N-209410 RX | 2018-02-16 | 2 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
amantadine | ANDA | 2023-04-26 |
amantadine hcl | ANDA | 2023-12-25 |
amantadine hydrochloride | ANDA | 2024-01-09 |
gocovri | New Drug Application | 2024-02-08 |
osmolex er | New Drug Application | 2024-02-08 |
symmetrel hard gel | ANDA | 2023-01-18 |
Expiration | Code | ||
---|---|---|---|
AMANTADINE HYDROCHLORIDE, GOCOVRI, ADAMAS OPERATIONS | |||
2024-08-24 | ODE-153 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Amantadine Hydrochloride, Gocovri, Adamas Operations | |||
11065213 | 2038-08-23 | DP | |
11077073 | 2038-08-23 | U-2106, U-2224, U-3180 | |
10154971 | 2034-12-04 | U-2459 | |
10646456 | 2034-06-17 | U-2808 | |
8741343 | 2030-12-02 | U-2106 | |
9867791 | 2030-12-02 | U-2106 | |
9867792 | 2030-12-02 | U-2106 | |
9867793 | 2030-12-02 | U-2106 | |
9877933 | 2030-12-02 | U-2224 | |
11197835 | 2030-12-02 | U-2106 | |
8389578 | 2028-01-22 | U-219, U-2105, U-3054 | |
8796337 | 2025-11-23 | U-219, U-2106, U-2497, U-3054 | |
8889740 | 2025-11-23 | DP | |
8895614 | 2025-11-23 | DP | |
8895615 | 2025-11-23 | U-219, U-2106, U-3054 | |
8895616 | 2025-11-23 | U-219, U-2106, U-3054 | |
8895617 | 2025-11-23 | U-219, U-2106, U-3054 | |
8895618 | 2025-11-23 | DP | |
Amantadine Hydrochloride, Osmolex Er, Adamas Operations | |||
10213393 | 2038-02-15 | U-20 | |
10213394 | 2038-02-15 | U-2497 | |
10500170 | 2038-02-15 | U-20 | |
10500171 | 2038-02-15 | U-2497 | |
10500172 | 2038-02-15 | U-2497 | |
10512617 | 2038-02-15 | U-2497 | |
8252331 | 2030-03-13 | DP | |
8574626 | 2025-11-28 | DP | U-20 |
8987333 | 2025-11-23 | DP | |
9072697 | 2025-11-23 | U-219, U-3054 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | 6 | 8 | 5 | 5 | 25 |
Traumatic brain injuries | D000070642 | — | S06 | 1 | 1 | 1 | 3 | 4 | 9 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 1 | 4 | 1 | — | 6 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 2 | 1 | — | 5 |
Cocaine-related disorders | D019970 | — | F14 | 1 | 3 | — | 1 | — | 5 |
Parkinsonian disorders | D020734 | HP_0001300 | G20.C | — | 1 | — | 1 | 1 | 3 |
Psychotic disorders | D011618 | — | F20.81 | 1 | — | 1 | 1 | — | 3 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 1 | — | 1 | — | 3 |
Postoperative pain | D010149 | — | G89.18 | — | — | — | 2 | — | 2 |
Delirium | D003693 | — | R41.0 | — | — | — | 2 | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyskinesias | D020820 | HP_0002310 | G24 | 1 | 2 | 6 | — | — | 8 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | 3 | — | 2 | 6 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 4 | — | — | 5 |
Recurrence | D012008 | — | — | — | 1 | 2 | — | — | 2 |
Hepatitis c | D006526 | — | B19.2 | — | 1 | 2 | — | — | 2 |
Sinusitis | D012852 | EFO_0007486 | J32 | — | — | 1 | — | 1 | 2 |
Cerebral infarction | D002544 | — | I63 | — | 1 | 1 | — | — | 1 |
Rhinosinusitis | D000096825 | — | — | — | — | 1 | — | — | 1 |
Sars-cov-2 | D000086402 | — | — | — | — | 1 | — | — | 1 |
Spinal curvatures | D013121 | — | M43.9 | — | 1 | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Human influenza | D007251 | EFO_0007328 | J11.1 | 1 | 4 | — | — | 2 | 6 |
Coma | D003128 | HP_0001259 | R40.2 | — | 1 | — | — | 2 | 3 |
Huntington disease | D006816 | Orphanet_399 | G10 | — | 1 | — | — | 1 | 2 |
Consciousness disorders | D003244 | — | — | 1 | 1 | — | — | — | 2 |
Brain injuries | D001930 | — | S06.9 | 1 | 1 | — | — | 1 | 2 |
Movement disorders | D009069 | HP_0100022 | — | 1 | 1 | — | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | 1 | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Intratracheal intubation | D007442 | — | — | — | 1 | — | — | — | 1 |
Hypoxia | D000860 | HP_0012418 | R09.02 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Aggression | D000374 | EFO_0003015 | — | — | — | — | — | 2 | 2 |
Multiple system atrophy | D019578 | — | — | — | — | — | — | 1 | 1 |
Neurologic gait disorders | D020233 | HP_0003376 | R26.1 | — | — | — | — | 1 | 1 |
Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | — | — | 1 | 1 |
Corticobasal degeneration | D000088282 | — | G31.85 | — | — | — | — | 1 | 1 |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 1 | 1 |
Disease progression | D018450 | — | — | — | — | — | — | 1 | 1 |
Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 1 | 1 |
Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | — | — | 1 | 1 |
Drug common name | Amantadine |
INN | amantadine |
Description | Amantadine is a member of the class of adamantanes that is used as an antiviral and antiparkinson drug. It has a role as an antiviral drug, an antiparkinson drug, a dopaminergic agent, an analgesic, a NMDA receptor antagonist and a non-narcotic analgesic. It is a primary aliphatic amine and a member of adamantanes. It is a conjugate base of an adamantan-1-aminium. It derives from a hydride of an adamantane. |
Classification | Small molecule |
Drug class | antivirals/antiparkinsonians (adamantane derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NC12CC3CC(CC(C3)C1)C2 |
PDB | — |
CAS-ID | 768-94-5 |
RxCUI | — |
ChEMBL ID | CHEMBL660 |
ChEBI ID | 2618 |
PubChem CID | 2130 |
DrugBank | DB00915 |
UNII ID | BF4C9Z1J53 (ChemIDplus, GSRS) |